Sanofi’s dengue vaccine scores 11th worldwide approval in Singapore

pharmafile | October 4, 2016 | News story | Sales and Marketing Sanofi, dengue, drug approval 

Sanofi Pasteur, the vaccines unit of the wider French firm, has announced that its dengue vaccine Dengvaxia has secured market approval in Singapore, the eleventh country in the world to approve it.

The product is due to be made publicly available in a few months and is the first vaccine to protect against all four strains of the virus. It is currently only approved for use in those between the ages of 12 and 45.

Adminstered in three doses over 12 months via injection, the vaccine is effective up to four years and is most effective in those who have contracted the disease before; according to 24 studies of over 41,000 participants, the vaccine offered an 81% success rate in those who had previous dengue infection versus a 38% success rate for those who hadn’t, the Helath Sciences Authourity (HSA) said. It has also been found to be less effective against the DENV-1 and DENV-2 strains of the virus. Overall, the vaccine was effective in reducing dengue illness by 60%, and reducing severe dengue illness by 84%.

The mosquito-borne disease is considered to threaten half the world’s population, with 400 million people affected each year, causing severe nausea bone pain, headaches, rashes, bleeding, and even death.

The vaccine has now been approved in Mexico, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and now Singapore.

Matt Fellows

Related Content

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …


Sanofi’s NSCLC drug gains EC approval

The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the …

Latest content